JP2002519324A - ＣＯＸ−２阻害剤およびｉＮＯＳ阻害剤を含んでなる薬学的組合わせ - Google Patents
ＣＯＸ−２阻害剤およびｉＮＯＳ阻害剤を含んでなる薬学的組合わせInfo
- Publication number
- JP2002519324A JP2002519324A JP2000556785A JP2000556785A JP2002519324A JP 2002519324 A JP2002519324 A JP 2002519324A JP 2000556785 A JP2000556785 A JP 2000556785A JP 2000556785 A JP2000556785 A JP 2000556785A JP 2002519324 A JP2002519324 A JP 2002519324A
- Authority
- JP
- Japan
- Prior art keywords
- quinazoline
- piperidine
- amine
- spiro
- fluorospiro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 title claims abstract description 23
- 229940111134 coxibs Drugs 0.000 title claims description 22
- 239000003112 inhibitor Substances 0.000 title abstract description 25
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 title description 34
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 11
- -1 nitro, hydroxymethyl Chemical group 0.000 claims description 76
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 125000000217 alkyl group Chemical group 0.000 claims description 28
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- 239000001257 hydrogen Substances 0.000 claims description 24
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 229910052760 oxygen Inorganic materials 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 20
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 19
- 229910052757 nitrogen Inorganic materials 0.000 claims description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 14
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 14
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 11
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 9
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 7
- 125000001424 substituent group Chemical group 0.000 claims description 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 6
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 6
- 241000282414 Homo sapiens Species 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 229960000590 celecoxib Drugs 0.000 claims description 5
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 125000003386 piperidinyl group Chemical group 0.000 claims description 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 3
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 2
- CVICEEPAFUYBJG-UHFFFAOYSA-N 5-chloro-2,2-difluoro-1,3-benzodioxole Chemical group C1=C(Cl)C=C2OC(F)(F)OC2=C1 CVICEEPAFUYBJG-UHFFFAOYSA-N 0.000 claims description 2
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims description 2
- 125000004414 alkyl thio group Chemical group 0.000 claims description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
- 125000004429 atom Chemical group 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000004965 chloroalkyl group Chemical group 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 229950005722 flosulide Drugs 0.000 claims description 2
- 125000005843 halogen group Chemical group 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- 229960001929 meloxicam Drugs 0.000 claims description 2
- CXJONBHNIJFARE-UHFFFAOYSA-N n-[6-(2,4-difluorophenoxy)-1-oxo-2,3-dihydroinden-5-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=2CCC(=O)C=2C=C1OC1=CC=C(F)C=C1F CXJONBHNIJFARE-UHFFFAOYSA-N 0.000 claims description 2
- 125000001624 naphthyl group Chemical group 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- MIMJSJSRRDZIPW-UHFFFAOYSA-N tilmacoxib Chemical compound C=1C=C(S(N)(=O)=O)C(F)=CC=1C=1OC(C)=NC=1C1CCCCC1 MIMJSJSRRDZIPW-UHFFFAOYSA-N 0.000 claims description 2
- 125000003003 spiro group Chemical group 0.000 claims 17
- 229910052698 phosphorus Inorganic materials 0.000 claims 11
- 239000011574 phosphorus Substances 0.000 claims 11
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 7
- RUZOQNAMPCLLFI-UHFFFAOYSA-N 5-fluorospiro[1h-quinazoline-2,4'-piperidine]-4-amine Chemical compound N1C2=CC=CC(F)=C2C(N)=NC21CCNCC2 RUZOQNAMPCLLFI-UHFFFAOYSA-N 0.000 claims 6
- YSIFOLULMFTZKL-UHFFFAOYSA-N spiro[1h-quinazoline-2,4'-piperidine]-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC21CCNCC2 YSIFOLULMFTZKL-UHFFFAOYSA-N 0.000 claims 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 150000001412 amines Chemical class 0.000 claims 2
- 150000007942 carboxylates Chemical class 0.000 claims 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 claims 2
- AKWKXFUXQQNUGE-UHFFFAOYSA-N (3-amino-4-chlorophenyl)-(4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(Cl)C(N)=C1 AKWKXFUXQQNUGE-UHFFFAOYSA-N 0.000 claims 1
- GIVFIZXMEZDGBR-UHFFFAOYSA-N (3-aminophenyl)-(4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=CC(N)=C1 GIVFIZXMEZDGBR-UHFFFAOYSA-N 0.000 claims 1
- KOCBGBJUDZNSJE-UHFFFAOYSA-N (4-amino-5,7-difluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-thiophen-2-ylmethanone Chemical compound N1C2=CC(F)=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=CS1 KOCBGBJUDZNSJE-UHFFFAOYSA-N 0.000 claims 1
- UVYGCLROCNKXPQ-UHFFFAOYSA-N (4-amino-5,8-difluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-chlorophenyl)methanone Chemical compound N1C2=C(F)C=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(Cl)C=C1 UVYGCLROCNKXPQ-UHFFFAOYSA-N 0.000 claims 1
- RSWKKGGFYGUXKX-UHFFFAOYSA-N (4-amino-5,8-difluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-thiophen-2-ylmethanone Chemical compound N1C2=C(F)C=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=CS1 RSWKKGGFYGUXKX-UHFFFAOYSA-N 0.000 claims 1
- DNFWRSPJYBBOPI-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(1,2-thiazol-4-yl)methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C=1C=NSC=1 DNFWRSPJYBBOPI-UHFFFAOYSA-N 0.000 claims 1
- XIWOHKSOWPQQKR-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(1,3-benzodioxol-5-yl)methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC11CCN(C(=O)C=2C=C3OCOC3=CC=2)CC1 XIWOHKSOWPQQKR-UHFFFAOYSA-N 0.000 claims 1
- VIMLGTXWXHFWLU-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(3,4-dichlorophenyl)methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(Cl)C(Cl)=C1 VIMLGTXWXHFWLU-UHFFFAOYSA-N 0.000 claims 1
- HKGKHOSURFYMEX-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-bromophenyl)methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(Br)C=C1 HKGKHOSURFYMEX-UHFFFAOYSA-N 0.000 claims 1
- LPHXOGYMVXBMGV-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-bromothiophen-2-yl)methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC(Br)=CS1 LPHXOGYMVXBMGV-UHFFFAOYSA-N 0.000 claims 1
- WQDRNIPMIVSODU-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-butylphenyl)methanone Chemical compound C1=CC(CCCC)=CC=C1C(=O)N1CCC2(N=C(N)C3=C(F)C=CC=C3N2)CC1 WQDRNIPMIVSODU-UHFFFAOYSA-N 0.000 claims 1
- OMUVOAMSPIQCOR-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-chloro-3-iodophenyl)methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(Cl)C(I)=C1 OMUVOAMSPIQCOR-UHFFFAOYSA-N 0.000 claims 1
- QVSKLCBLEFIJIU-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-chlorophenyl)methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(Cl)C=C1 QVSKLCBLEFIJIU-UHFFFAOYSA-N 0.000 claims 1
- QHHPFGJIVBDRLM-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-ethylphenyl)methanone Chemical compound C1=CC(CC)=CC=C1C(=O)N1CCC2(N=C(N)C3=C(F)C=CC=C3N2)CC1 QHHPFGJIVBDRLM-UHFFFAOYSA-N 0.000 claims 1
- HYADBWLWDQEHQC-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-ethynylphenyl)methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(C#C)C=C1 HYADBWLWDQEHQC-UHFFFAOYSA-N 0.000 claims 1
- ZTPZBIJLCSPGQL-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(5-bromothiophen-2-yl)methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(Br)S1 ZTPZBIJLCSPGQL-UHFFFAOYSA-N 0.000 claims 1
- UVOWHTMQZPDFMX-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(5-bromothiophen-3-yl)methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CSC(Br)=C1 UVOWHTMQZPDFMX-UHFFFAOYSA-N 0.000 claims 1
- PSSXHJXRSQJUCU-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(5-ethylthiophen-2-yl)methanone Chemical compound S1C(CC)=CC=C1C(=O)N1CCC2(N=C(N)C3=C(F)C=CC=C3N2)CC1 PSSXHJXRSQJUCU-UHFFFAOYSA-N 0.000 claims 1
- IZTDKOVHEGYKPL-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(6-chloropyridin-3-yl)methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(Cl)N=C1 IZTDKOVHEGYKPL-UHFFFAOYSA-N 0.000 claims 1
- WFHLOVTZLHSUJR-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-[4-(1,3-thiazol-2-yl)phenyl]methanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C(C=C1)=CC=C1C1=NC=CS1 WFHLOVTZLHSUJR-UHFFFAOYSA-N 0.000 claims 1
- ABHMXNAQNFTILP-UHFFFAOYSA-N (4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-imidazol-1-ylmethanone Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)N1C=CN=C1 ABHMXNAQNFTILP-UHFFFAOYSA-N 0.000 claims 1
- YOGMHFXUEGAVGP-UHFFFAOYSA-N (4-amino-5-hydroxyspiro[1H-quinazoline-2,4'-piperidine]-1'-yl)-(4-bromophenyl)methanone Chemical compound BrC1=CC=C(C(=O)N2CCC3(CC2)NC2=CC=CC(=C2C(=N3)N)O)C=C1 YOGMHFXUEGAVGP-UHFFFAOYSA-N 0.000 claims 1
- HUGDORSEMMDVLL-UHFFFAOYSA-N (4-aminophenyl)-(4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(N)C=C1 HUGDORSEMMDVLL-UHFFFAOYSA-N 0.000 claims 1
- YSLVFEKXFLRWJB-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(2-methylphenyl)methanone Chemical compound CC1=CC=CC=C1C(=O)N1CCC2(N=C(N)C3=CC=CC=C3N2)CC1 YSLVFEKXFLRWJB-UHFFFAOYSA-N 0.000 claims 1
- YTFXUYQLAYFSDK-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(2-nitrophenyl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=CC=C1[N+]([O-])=O YTFXUYQLAYFSDK-UHFFFAOYSA-N 0.000 claims 1
- PQURLOMPBCHPGL-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(3-fluoro-4-methylphenyl)methanone Chemical compound C1=C(F)C(C)=CC=C1C(=O)N1CCC2(N=C(N)C3=CC=CC=C3N2)CC1 PQURLOMPBCHPGL-UHFFFAOYSA-N 0.000 claims 1
- ATCGMXBENMJJLF-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(3-methylphenyl)methanone Chemical compound CC1=CC=CC(C(=O)N2CCC3(CC2)N=C(N)C2=CC=CC=C2N3)=C1 ATCGMXBENMJJLF-UHFFFAOYSA-N 0.000 claims 1
- CCBWQNZCZLKXGW-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(3-nitrophenyl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=CC([N+]([O-])=O)=C1 CCBWQNZCZLKXGW-UHFFFAOYSA-N 0.000 claims 1
- VNWSZDTZAXJWTA-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-bromophenyl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(Br)C=C1 VNWSZDTZAXJWTA-UHFFFAOYSA-N 0.000 claims 1
- RSHKJRVJSVODHV-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-chlorophenyl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(Cl)C=C1 RSHKJRVJSVODHV-UHFFFAOYSA-N 0.000 claims 1
- ZHMUHIIKTOAYBJ-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-ethylphenyl)methanone Chemical compound C1=CC(CC)=CC=C1C(=O)N1CCC2(N=C(N)C3=CC=CC=C3N2)CC1 ZHMUHIIKTOAYBJ-UHFFFAOYSA-N 0.000 claims 1
- ZYTYCDYFRYWVRC-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-fluorophenyl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(F)C=C1 ZYTYCDYFRYWVRC-UHFFFAOYSA-N 0.000 claims 1
- UBAXEWSWJWAHFE-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-iodophenyl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(I)C=C1 UBAXEWSWJWAHFE-UHFFFAOYSA-N 0.000 claims 1
- OHNSXMZWFQQTCM-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-methoxyphenyl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)N1CCC2(N=C(N)C3=CC=CC=C3N2)CC1 OHNSXMZWFQQTCM-UHFFFAOYSA-N 0.000 claims 1
- WVIIEGBETUCHMM-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-methylphenyl)methanone Chemical compound C1=CC(C)=CC=C1C(=O)N1CCC2(N=C(N)C3=CC=CC=C3N2)CC1 WVIIEGBETUCHMM-UHFFFAOYSA-N 0.000 claims 1
- PDOBPTCTJCNTFG-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-methylsulfonylphenyl)methanone Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C(=O)N1CCC2(N=C(N)C3=CC=CC=C3N2)CC1 PDOBPTCTJCNTFG-UHFFFAOYSA-N 0.000 claims 1
- NJTHXCSIFDORLB-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-nitrophenyl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C([N+]([O-])=O)C=C1 NJTHXCSIFDORLB-UHFFFAOYSA-N 0.000 claims 1
- STMUJZVGRUGXPP-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-phenylmethoxyphenyl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C(C=C1)=CC=C1OCC1=CC=CC=C1 STMUJZVGRUGXPP-UHFFFAOYSA-N 0.000 claims 1
- BKEHWSDXDOKAKY-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(4-pyrrol-1-ylphenyl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C(C=C1)=CC=C1N1C=CC=C1 BKEHWSDXDOKAKY-UHFFFAOYSA-N 0.000 claims 1
- OPTLWKIMIHXNQP-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(5-chlorothiophen-2-yl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(Cl)S1 OPTLWKIMIHXNQP-UHFFFAOYSA-N 0.000 claims 1
- CDTAQGVWXTWJSL-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-(furan-2-yl)methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=CO1 CDTAQGVWXTWJSL-UHFFFAOYSA-N 0.000 claims 1
- FOHCTSUZLZRUHD-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-[4-(trifluoromethyl)phenyl]methanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(C(F)(F)F)C=C1 FOHCTSUZLZRUHD-UHFFFAOYSA-N 0.000 claims 1
- CDMGWLJJDGVEHM-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-phenylmethanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=CC=C1 CDMGWLJJDGVEHM-UHFFFAOYSA-N 0.000 claims 1
- IZBCDOMUJBDFRK-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-pyridin-2-ylmethanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=CC=N1 IZBCDOMUJBDFRK-UHFFFAOYSA-N 0.000 claims 1
- RZQBITLJVDCTCQ-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-pyridin-3-ylmethanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=CN=C1 RZQBITLJVDCTCQ-UHFFFAOYSA-N 0.000 claims 1
- QPQYFHNRSWYIRL-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-pyridin-4-ylmethanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=NC=C1 QPQYFHNRSWYIRL-UHFFFAOYSA-N 0.000 claims 1
- YCPVARZUSFKJFC-UHFFFAOYSA-N (4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-thiophen-2-ylmethanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=CS1 YCPVARZUSFKJFC-UHFFFAOYSA-N 0.000 claims 1
- YHJPPEXZUKHKKE-UHFFFAOYSA-N (5-bromo-2-methoxyphenyl)methyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound COC1=CC=C(Br)C=C1COC(=O)N1CCC2(N=C(N)C3=C(F)C=CC=C3N2)CC1 YHJPPEXZUKHKKE-UHFFFAOYSA-N 0.000 claims 1
- BANAKXZRCPMACJ-UHFFFAOYSA-N 1'-(1,3-thiazol-2-yl)spiro[1h-quinazoline-2,4'-piperidine]-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C1=NC=CS1 BANAKXZRCPMACJ-UHFFFAOYSA-N 0.000 claims 1
- IRPWAGHGBJTSMA-UHFFFAOYSA-N 1'-(3-methyl-1,2,4-oxadiazol-5-yl)spiro[1h-quinazoline-2,4'-piperidine]-4-amine Chemical compound CC1=NOC(N2CCC3(CC2)N=C(N)C2=CC=CC=C2N3)=N1 IRPWAGHGBJTSMA-UHFFFAOYSA-N 0.000 claims 1
- STPBJMQHABDYOU-UHFFFAOYSA-N 1'-benzylspiro[1H-quinazoline-2,3'-pyrrolidine]-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1(C1)CCN1CC1=CC=CC=C1 STPBJMQHABDYOU-UHFFFAOYSA-N 0.000 claims 1
- PLVDEUNFGOERLC-UHFFFAOYSA-N 1'-benzylspiro[1h-quinazoline-2,3'-piperidine]-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1(C1)CCCN1CC1=CC=CC=C1 PLVDEUNFGOERLC-UHFFFAOYSA-N 0.000 claims 1
- GHNOXODQBPONQP-UHFFFAOYSA-N 1'-benzylspiro[1h-quinazoline-2,4'-piperidine]-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1CC1=CC=CC=C1 GHNOXODQBPONQP-UHFFFAOYSA-N 0.000 claims 1
- ICXFAHOEALHNMX-UHFFFAOYSA-N 1'-methylsulfonylspiro[1h-quinazoline-2,4'-piperidine]-4-amine Chemical compound C1CN(S(=O)(=O)C)CCC21N=C(N)C1=CC=CC=C1N2 ICXFAHOEALHNMX-UHFFFAOYSA-N 0.000 claims 1
- LIWDTGMJUGTXEP-UHFFFAOYSA-N 1,2-dihydroquinazolin-4-amine Chemical compound C1=CC=C2C(N)=NCNC2=C1 LIWDTGMJUGTXEP-UHFFFAOYSA-N 0.000 claims 1
- WOWHOIWNMKITEP-UHFFFAOYSA-N 1-(4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)-2-[2-(trifluoromethyl)phenyl]ethanone Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)CC1=CC=CC=C1C(F)(F)F WOWHOIWNMKITEP-UHFFFAOYSA-N 0.000 claims 1
- LGVQESSANSAKBV-UHFFFAOYSA-N 1-(4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)butan-1-one Chemical compound C1CN(C(=O)CCC)CCC21N=C(N)C1=CC=CC=C1N2 LGVQESSANSAKBV-UHFFFAOYSA-N 0.000 claims 1
- BSJQHSXKBRPGOU-UHFFFAOYSA-N 1-(4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-yl)ethanone Chemical compound C1CN(C(=O)C)CCC21N=C(N)C1=CC=CC=C1N2 BSJQHSXKBRPGOU-UHFFFAOYSA-N 0.000 claims 1
- HIPMKGGRAYZDJC-UHFFFAOYSA-N 1-[3-(4'-amino-5'-fluorospiro[piperidine-4,2'-quinazoline]-1'-yl)propyl]pyridin-2-one Chemical compound C1=CC=CC(=O)N1CCCN1C2=CC=CC(F)=C2C(N)=NC21CCNCC2 HIPMKGGRAYZDJC-UHFFFAOYSA-N 0.000 claims 1
- KNVKFSJVWVRZQB-UHFFFAOYSA-N 1-benzofuran-2-ylmethyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound N1C2=CC=CC(F)=C2C(N)=NC11CCN(C(=O)OCC=2OC3=CC=CC=C3C=2)CC1 KNVKFSJVWVRZQB-UHFFFAOYSA-N 0.000 claims 1
- ZCULUGBJSMGCDG-UHFFFAOYSA-N 1-methyl-2-phenyl-2h-quinazolin-4-amine Chemical compound N1=C(N)C2=CC=CC=C2N(C)C1C1=CC=CC=C1 ZCULUGBJSMGCDG-UHFFFAOYSA-N 0.000 claims 1
- HILXMJVTMIHIQK-UHFFFAOYSA-N 2,2,2-trifluoroethyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound N1C2=CC=CC(F)=C2C(N)=NC21CCN(C(=O)OCC(F)(F)F)CC2 HILXMJVTMIHIQK-UHFFFAOYSA-N 0.000 claims 1
- GOAQIFIXXGXKFF-UHFFFAOYSA-N 2,2-dimethyl-1h-quinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC(C)(C)NC2=C1 GOAQIFIXXGXKFF-UHFFFAOYSA-N 0.000 claims 1
- OESYASHKFVCSTL-UHFFFAOYSA-N 2-(1,3-thiazol-2-yl)-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=NC=CS1 OESYASHKFVCSTL-UHFFFAOYSA-N 0.000 claims 1
- OSFDRCPUKQFYBL-UHFFFAOYSA-N 2-(2-aminoethyl)-1,2-dihydroquinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC(CCN)NC2=C1 OSFDRCPUKQFYBL-UHFFFAOYSA-N 0.000 claims 1
- PZFBPUAOCMMRLZ-UHFFFAOYSA-N 2-(2-trimethylsilylethynyl)-1,2-dihydroquinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC(C#C[Si](C)(C)C)NC2=C1 PZFBPUAOCMMRLZ-UHFFFAOYSA-N 0.000 claims 1
- DRBTXTOYZCLBJI-UHFFFAOYSA-N 2-(3-aminopropyl)-1,2-dihydroquinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC(CCCN)NC2=C1 DRBTXTOYZCLBJI-UHFFFAOYSA-N 0.000 claims 1
- HLWCINSTSGDTIB-UHFFFAOYSA-N 2-(5-nitrothiophen-2-yl)-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=CC=C([N+]([O-])=O)S1 HLWCINSTSGDTIB-UHFFFAOYSA-N 0.000 claims 1
- RIOVUWRMOKFDQS-UHFFFAOYSA-N 2-(furan-2-yl)-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=CC=CO1 RIOVUWRMOKFDQS-UHFFFAOYSA-N 0.000 claims 1
- UIIANCNAHLNGKW-UHFFFAOYSA-N 2-anthracen-9-yl-1,2-dihydroquinazolin-4-amine Chemical compound C1=CC=C2C(C3N=C(C4=CC=CC=C4N3)N)=C(C=CC=C3)C3=CC2=C1 UIIANCNAHLNGKW-UHFFFAOYSA-N 0.000 claims 1
- REDQGPXPTDODAT-UHFFFAOYSA-N 2-cyanoethyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound N1C2=CC=CC(F)=C2C(N)=NC21CCN(C(=O)OCCC#N)CC2 REDQGPXPTDODAT-UHFFFAOYSA-N 0.000 claims 1
- YQSLFNIIJBAELO-UHFFFAOYSA-N 2-cyclobutyl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1CCC1 YQSLFNIIJBAELO-UHFFFAOYSA-N 0.000 claims 1
- TWDKMKHCHFFGDT-UHFFFAOYSA-N 2-cyclobutyl-5-fluoro-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1C1CCC1 TWDKMKHCHFFGDT-UHFFFAOYSA-N 0.000 claims 1
- CODFUQOUEHCCNF-UHFFFAOYSA-N 2-cyclopentyl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1CCCC1 CODFUQOUEHCCNF-UHFFFAOYSA-N 0.000 claims 1
- MXQUJZRTIGEIOF-UHFFFAOYSA-N 2-cyclopropyl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1CC1 MXQUJZRTIGEIOF-UHFFFAOYSA-N 0.000 claims 1
- YFDYGSPBBLYHLX-UHFFFAOYSA-N 2-cyclopropyl-1-methyl-2h-quinazolin-4-amine Chemical compound N1=C(N)C2=CC=CC=C2N(C)C1C1CC1 YFDYGSPBBLYHLX-UHFFFAOYSA-N 0.000 claims 1
- MFRCBOKLESMGRI-UHFFFAOYSA-N 2-ethyl-1,2-dihydroquinazolin-4-amine Chemical compound C1=CC=C2C(N)=NC(CC)NC2=C1 MFRCBOKLESMGRI-UHFFFAOYSA-N 0.000 claims 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- CLTSEWJWIDOHJZ-UHFFFAOYSA-N 2-methoxyethyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OCCOC)CCC21N=C(N)C1=C(F)C=CC=C1N2 CLTSEWJWIDOHJZ-UHFFFAOYSA-N 0.000 claims 1
- FUCNABOVCYXQIG-UHFFFAOYSA-N 2-methylpropyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OCC(C)C)CCC21N=C(N)C1=C(F)C=CC=C1N2 FUCNABOVCYXQIG-UHFFFAOYSA-N 0.000 claims 1
- XNWAEPWOAAIYIV-UHFFFAOYSA-N 2-phenoxyethyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)OCCOC1=CC=CC=C1 XNWAEPWOAAIYIV-UHFFFAOYSA-N 0.000 claims 1
- VRHGJUOMOHIJKK-UHFFFAOYSA-N 2-phenyl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=CC=CC=C1 VRHGJUOMOHIJKK-UHFFFAOYSA-N 0.000 claims 1
- FWTHCXKFLJTGPK-UHFFFAOYSA-N 2-phenylethyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)OCCC1=CC=CC=C1 FWTHCXKFLJTGPK-UHFFFAOYSA-N 0.000 claims 1
- HRFIDKBTEAWKLR-UHFFFAOYSA-N 2-pyridin-4-yl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=CC=NC=C1 HRFIDKBTEAWKLR-UHFFFAOYSA-N 0.000 claims 1
- YXOPNVUMAUDDSS-UHFFFAOYSA-N 2-thiophen-2-yl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=CC=CS1 YXOPNVUMAUDDSS-UHFFFAOYSA-N 0.000 claims 1
- PGZZCWMDAWIJPR-UHFFFAOYSA-N 3-chloropropyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound N1C2=CC=CC(F)=C2C(N)=NC21CCN(C(=O)OCCCCl)CC2 PGZZCWMDAWIJPR-UHFFFAOYSA-N 0.000 claims 1
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 claims 1
- ASRPSFSSAFCIJP-UHFFFAOYSA-N 3-phenoxypropyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)OCCCOC1=CC=CC=C1 ASRPSFSSAFCIJP-UHFFFAOYSA-N 0.000 claims 1
- ACBJGIJRAZZUQW-UHFFFAOYSA-N 3-phenylpropyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)OCCCC1=CC=CC=C1 ACBJGIJRAZZUQW-UHFFFAOYSA-N 0.000 claims 1
- CPHYQCVJQCQJHU-UHFFFAOYSA-N 4,4,4-trifluorobutyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound N1C2=CC=CC(F)=C2C(N)=NC21CCN(C(=O)OCCCC(F)(F)F)CC2 CPHYQCVJQCQJHU-UHFFFAOYSA-N 0.000 claims 1
- JREYTKUJENPMHF-UHFFFAOYSA-N 4-(4-amino-1,2-dihydroquinazolin-2-yl)benzonitrile Chemical compound N1C2=CC=CC=C2C(N)=NC1C1=CC=C(C#N)C=C1 JREYTKUJENPMHF-UHFFFAOYSA-N 0.000 claims 1
- ZOOSQLBAMVUYMU-UHFFFAOYSA-N 4-(4-amino-5,7-difluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carbonyl)benzonitrile Chemical compound N1C2=CC(F)=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(C#N)C=C1 ZOOSQLBAMVUYMU-UHFFFAOYSA-N 0.000 claims 1
- SYBIKAPEJWFEAV-UHFFFAOYSA-N 4-(4-amino-5,8-difluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carbonyl)benzonitrile Chemical compound N1C2=C(F)C=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(C#N)C=C1 SYBIKAPEJWFEAV-UHFFFAOYSA-N 0.000 claims 1
- QBEPROIELNJTPN-UHFFFAOYSA-N 4-(4-amino-5-chlorospiro[1h-quinazoline-2,4'-piperidine]-1'-carbonyl)benzonitrile Chemical compound N1C2=CC=CC(Cl)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(C#N)C=C1 QBEPROIELNJTPN-UHFFFAOYSA-N 0.000 claims 1
- VXTIJEHJPZTWSC-UHFFFAOYSA-N 4-(4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carbonyl)-2-fluorobenzonitrile Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(C#N)C(F)=C1 VXTIJEHJPZTWSC-UHFFFAOYSA-N 0.000 claims 1
- MUXAPSCMXSGRMK-UHFFFAOYSA-N 4-(4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carbonyl)-2-methylbenzonitrile Chemical compound C1=C(C#N)C(C)=CC(C(=O)N2CCC3(CC2)N=C(N)C2=C(F)C=CC=C2N3)=C1 MUXAPSCMXSGRMK-UHFFFAOYSA-N 0.000 claims 1
- CKXPAAJCRIZEOC-UHFFFAOYSA-N 4-(4-amino-5-hydroxyspiro[1H-quinazoline-2,4'-piperidine]-1'-carbonyl)benzonitrile Chemical compound C(#N)C1=CC=C(C(=O)N2CCC3(NC4=CC=CC(=C4C(=N3)N)O)CC2)C=C1 CKXPAAJCRIZEOC-UHFFFAOYSA-N 0.000 claims 1
- OGFYIRCPFJGCPD-UHFFFAOYSA-N 4-(4-amino-5-methoxyspiro[1h-quinazoline-2,4'-piperidine]-1'-carbonyl)benzonitrile Chemical compound N1=C(N)C=2C(OC)=CC=CC=2NC1(CC1)CCN1C(=O)C1=CC=C(C#N)C=C1 OGFYIRCPFJGCPD-UHFFFAOYSA-N 0.000 claims 1
- REINVSVZVLMNRB-UHFFFAOYSA-N 4-(4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-carbonyl)benzenesulfonamide Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(S(N)(=O)=O)C=C1 REINVSVZVLMNRB-UHFFFAOYSA-N 0.000 claims 1
- RNXCOOITKILVQC-UHFFFAOYSA-N 4-(4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-carbonyl)benzoic acid Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(C(O)=O)C=C1 RNXCOOITKILVQC-UHFFFAOYSA-N 0.000 claims 1
- LAHZEKUNLGBBCY-UHFFFAOYSA-N 4-(4-aminospiro[1h-quinazoline-2,4'-piperidine]-1'-carbonyl)benzonitrile Chemical compound N1C2=CC=CC=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(C#N)C=C1 LAHZEKUNLGBBCY-UHFFFAOYSA-N 0.000 claims 1
- JLAKCHGEEBPDQI-UHFFFAOYSA-N 4-(4-fluorobenzyl)piperidine Chemical compound C1=CC(F)=CC=C1CC1CCNCC1 JLAKCHGEEBPDQI-UHFFFAOYSA-N 0.000 claims 1
- VFEKEWYYJURFAY-UHFFFAOYSA-N 4-chlorobutyl 4-amino-5,8-difluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound N1C2=C(F)C=CC(F)=C2C(N)=NC21CCN(C(=O)OCCCCCl)CC2 VFEKEWYYJURFAY-UHFFFAOYSA-N 0.000 claims 1
- TWEHLZWFXKAKJA-UHFFFAOYSA-N 4-chlorobutyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound N1C2=CC=CC(F)=C2C(N)=NC21CCN(C(=O)OCCCCCl)CC2 TWEHLZWFXKAKJA-UHFFFAOYSA-N 0.000 claims 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- PAMAGZZQYDQEPT-UHFFFAOYSA-N 4-phenylbutyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)OCCCCC1=CC=CC=C1 PAMAGZZQYDQEPT-UHFFFAOYSA-N 0.000 claims 1
- NTSNKFYZLVZBHJ-UHFFFAOYSA-N 5'-fluoro-1'-[2-(4-methyl-1,3-thiazol-5-yl)ethyl]spiro[piperidine-4,2'-quinazoline]-4'-amine Chemical compound CC=1N=CSC=1CCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 NTSNKFYZLVZBHJ-UHFFFAOYSA-N 0.000 claims 1
- MPIJKWLZLLAICB-UHFFFAOYSA-N 5-(4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carbonyl)pyridine-2-carbonitrile Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(C#N)N=C1 MPIJKWLZLLAICB-UHFFFAOYSA-N 0.000 claims 1
- ZBZXORNPMDSVBO-UHFFFAOYSA-N 5-chloro-2-(furan-2-yl)-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC(Cl)=C2C(N)=NC1C1=CC=CO1 ZBZXORNPMDSVBO-UHFFFAOYSA-N 0.000 claims 1
- KZMMWKJKRXYXRH-UHFFFAOYSA-N 5-chloro-2-thiophen-2-yl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC(Cl)=C2C(N)=NC1C1=CC=CS1 KZMMWKJKRXYXRH-UHFFFAOYSA-N 0.000 claims 1
- SVLIWQZMYTWKEX-UHFFFAOYSA-N 5-chloropentyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound N1C2=CC=CC(F)=C2C(N)=NC21CCN(C(=O)OCCCCCCl)CC2 SVLIWQZMYTWKEX-UHFFFAOYSA-N 0.000 claims 1
- ADRXNSWTWMXBHN-UHFFFAOYSA-N 5-fluoro-2-(furan-2-yl)-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1C1=CC=CO1 ADRXNSWTWMXBHN-UHFFFAOYSA-N 0.000 claims 1
- WHZFSGZHOACEEC-UHFFFAOYSA-N 5-fluoro-2-[2-(trifluoromethyl)phenyl]-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1C1=CC=CC=C1C(F)(F)F WHZFSGZHOACEEC-UHFFFAOYSA-N 0.000 claims 1
- QFNLYCUBYXJYKQ-UHFFFAOYSA-N 5-fluoro-2-phenyl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1C1=CC=CC=C1 QFNLYCUBYXJYKQ-UHFFFAOYSA-N 0.000 claims 1
- OGKZGPSVQKXXOY-UHFFFAOYSA-N 5-fluoro-2-thiophen-2-yl-1,2-dihydroquinazolin-4-amine Chemical compound N1C2=CC=CC(F)=C2C(N)=NC1C1=CC=CS1 OGKZGPSVQKXXOY-UHFFFAOYSA-N 0.000 claims 1
- BWQKVQOXURJROY-UHFFFAOYSA-N 5-fluorospiro[1h-quinazoline-2,3'-azetidine]-4-amine Chemical compound N1C2=CC=CC(F)=C2C(N)=NC21CNC2 BWQKVQOXURJROY-UHFFFAOYSA-N 0.000 claims 1
- VOXFNKYBOJQVJL-UHFFFAOYSA-N 6-chlorohexyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound N1C2=CC=CC(F)=C2C(N)=NC21CCN(C(=O)OCCCCCCCl)CC2 VOXFNKYBOJQVJL-UHFFFAOYSA-N 0.000 claims 1
- MPHRCTFJKXIKCN-UHFFFAOYSA-N C1(=CC=CC=C1)COCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 Chemical compound C1(=CC=CC=C1)COCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 MPHRCTFJKXIKCN-UHFFFAOYSA-N 0.000 claims 1
- CXBNUXJIHBXANI-UHFFFAOYSA-N C1(=CC=CC=C1)NCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 Chemical compound C1(=CC=CC=C1)NCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 CXBNUXJIHBXANI-UHFFFAOYSA-N 0.000 claims 1
- WSUGKXIMMBAJLL-UHFFFAOYSA-N C1(=CC=CC=C1)SCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 Chemical compound C1(=CC=CC=C1)SCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 WSUGKXIMMBAJLL-UHFFFAOYSA-N 0.000 claims 1
- VHWJKNADPXGAPZ-UHFFFAOYSA-N C1CN(CCC12N=C(C3=C(N2C=N)C=CC=C3F)N)C4=CC=CS4 Chemical compound C1CN(CCC12N=C(C3=C(N2C=N)C=CC=C3F)N)C4=CC=CS4 VHWJKNADPXGAPZ-UHFFFAOYSA-N 0.000 claims 1
- DUVFTWSPNHUXJD-UHFFFAOYSA-N CSCCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 Chemical compound CSCCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 DUVFTWSPNHUXJD-UHFFFAOYSA-N 0.000 claims 1
- UUWXJILVVQMLCK-UHFFFAOYSA-N CSCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 Chemical compound CSCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 UUWXJILVVQMLCK-UHFFFAOYSA-N 0.000 claims 1
- ABUUEHASPZQEEC-UHFFFAOYSA-N N1=C(C=CC=C1)CCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 Chemical compound N1=C(C=CC=C1)CCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 ABUUEHASPZQEEC-UHFFFAOYSA-N 0.000 claims 1
- FAGCRRQWCRFLFK-UHFFFAOYSA-N N1=C(C=CC=C1)CCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 Chemical compound N1=C(C=CC=C1)CCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 FAGCRRQWCRFLFK-UHFFFAOYSA-N 0.000 claims 1
- UIFMUEINMFLQOH-UHFFFAOYSA-N N1=C(C=CC=C1)SCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 Chemical compound N1=C(C=CC=C1)SCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 UIFMUEINMFLQOH-UHFFFAOYSA-N 0.000 claims 1
- DNRUYZRJGQLPNQ-UHFFFAOYSA-N N1=CC(=CC=C1)CCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 Chemical compound N1=CC(=CC=C1)CCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 DNRUYZRJGQLPNQ-UHFFFAOYSA-N 0.000 claims 1
- YQZQMZBHZNUFFY-UHFFFAOYSA-N S1C(=CC=C1)CCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 Chemical compound S1C(=CC=C1)CCCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 YQZQMZBHZNUFFY-UHFFFAOYSA-N 0.000 claims 1
- FPVMAKQLMGHGHN-UHFFFAOYSA-N S1C(=CC=C1)CCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 Chemical compound S1C(=CC=C1)CCN1C2(N=C(C3=C(C=CC=C13)F)N)CCNCC2 FPVMAKQLMGHGHN-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- CVXBEEMKQHEXEN-UHFFFAOYSA-N carbaryl Chemical compound C1=CC=C2C(OC(=O)NC)=CC=CC2=C1 CVXBEEMKQHEXEN-UHFFFAOYSA-N 0.000 claims 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims 1
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims 1
- 229940095102 methyl benzoate Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- HRJPPZFUNGWEBZ-UHFFFAOYSA-N o-ethyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carbothioate Chemical compound C1CN(C(=S)OCC)CCC21N=C(N)C1=C(F)C=CC=C1N2 HRJPPZFUNGWEBZ-UHFFFAOYSA-N 0.000 claims 1
- GYQIFXOUPFHASL-UHFFFAOYSA-N propan-2-yl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound C1CN(C(=O)OC(C)C)CCC21N=C(N)C1=C(F)C=CC=C1N2 GYQIFXOUPFHASL-UHFFFAOYSA-N 0.000 claims 1
- QUEZQVVHMOJXGT-UHFFFAOYSA-N propan-2-yl 4-aminospiro[1H-quinazoline-2,4'-piperidine]-1'-carboxylate Chemical compound NC1=NC2(NC3=CC=CC=C13)CCN(CC2)C(=O)OC(C)C QUEZQVVHMOJXGT-UHFFFAOYSA-N 0.000 claims 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 1
- QBJQGVHAJXIHGL-UHFFFAOYSA-N s-ethyl 4-amino-5-fluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carbothioate Chemical compound C1CN(C(=O)SCC)CCC21N=C(N)C1=C(F)C=CC=C1N2 QBJQGVHAJXIHGL-UHFFFAOYSA-N 0.000 claims 1
- RIWTXZWXGVDJBI-UHFFFAOYSA-N spiro[1h-quinazoline-2,1'-cyclohexane]-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC21CCCCC2 RIWTXZWXGVDJBI-UHFFFAOYSA-N 0.000 claims 1
- YAGBUQONHWCOLW-UHFFFAOYSA-N spiro[1h-quinazoline-2,1'-cyclopentane]-4-amine Chemical compound N1C2=CC=CC=C2C(N)=NC21CCCC2 YAGBUQONHWCOLW-UHFFFAOYSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 abstract description 12
- 230000004054 inflammatory process Effects 0.000 abstract description 11
- 102000008299 Nitric Oxide Synthase Human genes 0.000 abstract description 3
- 108010021487 Nitric Oxide Synthase Proteins 0.000 abstract description 3
- 238000011260 co-administration Methods 0.000 abstract description 2
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 abstract 1
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 34
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 33
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 8
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 8
- 239000000679 carrageenan Substances 0.000 description 8
- 235000010418 carrageenan Nutrition 0.000 description 8
- 229920001525 carrageenan Polymers 0.000 description 8
- 229940113118 carrageenan Drugs 0.000 description 8
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 150000003180 prostaglandins Chemical class 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 206010003246 arthritis Diseases 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 5
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 4
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 210000002683 foot Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000004968 inflammatory condition Effects 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 230000035479 physiological effects, processes and functions Effects 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002921 anti-spasmodic effect Effects 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 238000012261 overproduction Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 102220240796 rs553605556 Human genes 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 1
- FJFMOBYDHGJDGV-UHFFFAOYSA-N 5-(4-amino-5,8-difluorospiro[1h-quinazoline-2,4'-piperidine]-1'-carbonyl)pyridine-2-carbonitrile;hydrochloride Chemical compound Cl.N1C2=C(F)C=CC(F)=C2C(N)=NC1(CC1)CCN1C(=O)C1=CC=C(C#N)N=C1 FJFMOBYDHGJDGV-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 229940124638 COX inhibitor Drugs 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 102000010907 Cyclooxygenase 2 Human genes 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000879758 Homo sapiens Sjoegren syndrome nuclear autoantigen 1 Proteins 0.000 description 1
- 206010065390 Inflammatory pain Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KCWZGJVSDFYRIX-YFKPBYRVSA-N N(gamma)-nitro-L-arginine methyl ester Chemical compound COC(=O)[C@@H](N)CCCN=C(N)N[N+]([O-])=O KCWZGJVSDFYRIX-YFKPBYRVSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102100037330 Sjoegren syndrome nuclear autoantigen 1 Human genes 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000004712 air sac Anatomy 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 229940125716 antipyretic agent Drugs 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 210000000544 articulatio talocruralis Anatomy 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical compound C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 1
- 229960000616 diflunisal Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- 230000001969 hypertrophic effect Effects 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000014987 limb edema Diseases 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000001129 nonadrenergic effect Effects 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 201000006292 polyarteritis nodosa Diseases 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 125000006296 sulfonyl amino group Chemical group [H]N(*)S(*)(=O)=O 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008409 synovial inflammation Effects 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9802333-6 | 1998-06-29 | ||
| SE9802333A SE9802333D0 (sv) | 1998-06-29 | 1998-06-29 | Novel combination |
| PCT/SE1999/001144 WO2000000200A1 (en) | 1998-06-29 | 1999-06-23 | A PHARMACEUTICAL COMBINATION COMPRISING A COX-2 INHIBITOR AND A iNOS INHIBITOR |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002519324A true JP2002519324A (ja) | 2002-07-02 |
Family
ID=20411898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000556785A Pending JP2002519324A (ja) | 1998-06-29 | 1999-06-23 | ＣＯＸ−２阻害剤およびｉＮＯＳ阻害剤を含んでなる薬学的組合わせ |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US6248745B1 (enExample) |
| EP (1) | EP1100505A1 (enExample) |
| JP (1) | JP2002519324A (enExample) |
| KR (1) | KR20010053252A (enExample) |
| CN (1) | CN1313769A (enExample) |
| AU (1) | AU4944799A (enExample) |
| BR (1) | BR9911666A (enExample) |
| CA (1) | CA2334515A1 (enExample) |
| CZ (1) | CZ20004896A3 (enExample) |
| EE (1) | EE200000766A (enExample) |
| ID (1) | ID27394A (enExample) |
| IL (1) | IL140022A0 (enExample) |
| IN (1) | IN2000MU00721A (enExample) |
| IS (1) | IS5794A (enExample) |
| MX (1) | MXPA00012162A (enExample) |
| NO (1) | NO20006559L (enExample) |
| PL (1) | PL345028A1 (enExample) |
| SE (1) | SE9802333D0 (enExample) |
| SK (1) | SK18482000A3 (enExample) |
| TR (1) | TR200003808T2 (enExample) |
| WO (1) | WO2000000200A1 (enExample) |
| ZA (1) | ZA200007076B (enExample) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004500358A (ja) * | 1999-12-08 | 2004-01-08 | ファルマシア コーポレイション | バイオアベイラビリティーが増加した固体状態のセレコキシブ |
| JP2003523958A (ja) * | 1999-12-23 | 2003-08-12 | ニトロメド インコーポレーテッド | ニトロソ化およびニトロシル化されたシクロオキシゲナーゼ−２の阻害剤、組成物ならびに使用法 |
| CA2432642A1 (en) * | 2000-12-21 | 2002-08-08 | Subhash P. Khanapure | Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| US7012098B2 (en) * | 2001-03-23 | 2006-03-14 | Pharmacia Corporation | Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers |
| AU2003207453A1 (en) * | 2002-01-07 | 2003-07-24 | Pharmacia Corp | Treatment of pain, inflammation, and inflammation-related disorders with a combination of a cyclooxygenase-2 selective inhibitor and aspirin |
| US7220749B2 (en) | 2002-06-11 | 2007-05-22 | Nitromed, Inc. | Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| US20040077691A1 (en) * | 2002-06-21 | 2004-04-22 | Medinox, Inc. | Hydroxamate derivatives of non-steroidal anti-inflammatory drugs |
| JP2005539089A (ja) | 2002-07-03 | 2005-12-22 | ニトロメッド インコーポレーティッド | ニトロソ化非ステロイド性抗炎症化合物、組成物および使用方法 |
| CA2493156A1 (en) | 2002-07-29 | 2004-02-05 | Nitromed, Inc. | Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| WO2004019986A1 (en) * | 2002-08-29 | 2004-03-11 | Schering Aktiengesellschaft | Methods of treating acute respiratory distress syndrome |
| PT1534305E (pt) | 2003-05-07 | 2007-02-28 | Osteologix As | Tratamento de afecções cartilagineas / osseas com sais de estroncio hidrosoluveis |
| ES2537898T3 (es) | 2005-10-25 | 2015-06-15 | Shionogi & Co., Ltd. | Derivados de aminotiazolidina y aminotetrahidrotiazepina como inhibidores de BACE 1 |
| JP2007275193A (ja) * | 2006-04-04 | 2007-10-25 | Fujifilm Corp | 光プローブおよび光断層画像化装置 |
| WO2008049376A1 (en) | 2006-10-25 | 2008-05-02 | Huawei Technologies Co., Ltd. | Processing location update request method, network entity, congestion control method and apparatus |
| CN101626787A (zh) * | 2007-01-19 | 2010-01-13 | 马林克罗特公司 | 诊断的和治疗的环氧合酶-2结合配体 |
| EP2151435A4 (en) | 2007-04-24 | 2011-09-14 | Shionogi & Co | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
| AU2008245082B8 (en) | 2007-04-24 | 2012-09-13 | Shionogi & Co., Ltd. | Aminodihydrothiazine derivatives substituted with a cyclic group |
| CA2716628A1 (en) * | 2008-03-24 | 2009-10-01 | Carolus Therapeutics, Inc. | Methods and compositions for treating atherosclerosis and related conditions |
| US8637504B2 (en) | 2008-06-13 | 2014-01-28 | Shionogi & Co., Ltd. | Sulfur-containing heterocyclic derivative having beta secretase inhibitory activity |
| WO2010047372A1 (ja) | 2008-10-22 | 2010-04-29 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害活性を有する２－アミノピリミジン－４－オンおよび２－アミノピリジン誘導体 |
| US8453441B2 (en) | 2008-11-06 | 2013-06-04 | Purdue Research Foundation | System and method for pump-controlled cylinder cushioning |
| MY145791A (en) * | 2009-05-25 | 2012-04-30 | Liang Woon San | A method for producing a nutraceutical composition and the nutraceutical produced by the method |
| RU2012129168A (ru) | 2009-12-11 | 2014-01-20 | Сионоги Энд Ко. Лтд. | Производные оксазина |
| WO2011077726A1 (ja) * | 2009-12-24 | 2011-06-30 | 塩野義製薬株式会社 | ４－アミノ－１，３－チアジンまたはオキサジン誘導体 |
| ES2575917T3 (es) | 2010-01-13 | 2016-07-04 | Basf Se | Nuevas variantes de mananasa |
| EP2545181B1 (en) | 2010-03-12 | 2014-11-12 | Council Of Scientific & Industrial Research | Process for the production of violacein and its derivative deoxyviolacein containing bioactive pigment from chromobacterium sp. (mtcc 5522) |
| DE102010030500A1 (de) | 2010-06-24 | 2011-12-29 | Heliatek Gmbh | Verdampfbares organisch halbleitendes Material und dessen Verwendung in einem optoelektronischen Bauelement |
| CA2816285A1 (en) | 2010-10-29 | 2012-05-03 | Shionogi & Co., Ltd. | Naphthyridine derivative |
| US9018219B2 (en) | 2010-10-29 | 2015-04-28 | Shionogi & Co., Ltd. | Fused aminodihydropyrimidine derivative |
| DE102011018604A1 (de) | 2011-04-25 | 2014-02-13 | Michael Friebe | Medikamenteninfusor für die Anwendung in stark magnetischen Umgebungen |
| WO2012147763A1 (ja) | 2011-04-26 | 2012-11-01 | 塩野義製薬株式会社 | オキサジン誘導体およびそれを含有するｂａｃｅ１阻害剤 |
| EP2713937A1 (de) | 2011-06-01 | 2014-04-09 | Josef Schweiger | Verbundkrone/verbundbrücke und verfahren zu deren herstellung |
| KR102128957B1 (ko) | 2011-10-07 | 2020-07-02 | 론자 리미티드 | 조절가능한 프로모터 |
| DE102012201426A1 (de) | 2012-02-01 | 2013-08-01 | Leibniz-Institut Für Polymerforschung Dresden E.V. | Verfahren zum verbinden von kunststoffen und verfahren zum lösen einer verbindung im kunststoffverbund und kunststoffverbund |
| DE102012007141A1 (de) | 2012-04-10 | 2013-10-10 | Bernhard Spindler | Jalousierbarer Rollladenpanzer |
| DE102012106428A1 (de) | 2012-07-17 | 2014-01-23 | Reha Technology GmbH | Vorrichtung zur therapeutischen Behandlung, System zur gerätegestützten Lokomotionstherapie und Verfahren zur Steuerung der Vorrichtung |
| WO2014024034A1 (es) | 2012-08-08 | 2014-02-13 | Choque Alberto Pati | Compostaje de residuos sólidos, liquidos y lodos biodegradables mediante humus de lombriz (eisenia foetida y especies similares) y mezclas de humus de lombriz y material estomacal con alto contenido de microrganismos |
| DE102012214452B4 (de) | 2012-08-14 | 2019-08-01 | Henkel Ag & Co. Kgaa | Vorrichtung zum Auftragen einer fadenförmigen Masse |
| DE102012016116A1 (de) | 2012-08-15 | 2014-02-20 | Josip Fellner | 360° Bag ln Box Spendersystem |
| DE102012214554A1 (de) | 2012-08-16 | 2014-02-20 | Robert Bosch Gmbh | Verfahren zur Überführung von Batterien in einen entladenen Zustand, Batteriemanagementsystem, Inverter, System zur Erzeugung einer Wechselspannung, Ladestromquelle und Kraftfahrzeug |
| DE102012108153A1 (de) | 2012-09-03 | 2014-03-06 | Ludwig-Maximilians-Universität München | Rohling und Verfahren zur Herstellung einer Dentalrestauration durch substraktive Bearbeitung |
| JP2016501827A (ja) | 2012-10-24 | 2016-01-21 | 塩野義製薬株式会社 | Ｂａｃｅ１阻害作用を有するジヒドロオキサジンまたはオキサゼピン誘導体 |
| DE102012112186A1 (de) | 2012-12-12 | 2014-06-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Materialverbund, Verfahren zu dessen Herstellung, daraus hergestelltes System und Anwendung desselben |
| EP2956041A2 (de) | 2013-02-15 | 2015-12-23 | Jochen Mertens | Mixer mit massnahmen zur reduzierung des eintrages von luftsauerstoff in den mixer-inhalt |
| DE102013101712B4 (de) | 2013-02-21 | 2020-05-28 | Heliatek Gmbh | Photoaktives organisches Material für optoelektronische Bauelemente |
| DE102013101713B4 (de) | 2013-02-21 | 2020-10-01 | Heliatek Gmbh | Photoaktives, organisches Material für optoelektronische Bauelemente |
| DE102013102366A1 (de) | 2013-03-10 | 2014-09-11 | Informium Ag | Vorrichtungen zur Herstellung und zum Auslesen eines Identifikationsmerkmals mit integriertem Kopierschutz |
| DE102013102365A1 (de) | 2013-03-10 | 2014-09-11 | Informium Ag | Identifikationsmerkmal mit integriertem Kopierschutz |
| DE102013102364A1 (de) | 2013-03-10 | 2014-09-11 | Informium Ag | Verfahren zur Herstellung eines Identifikationsmerkmals mit integriertem Kopierschutz |
| DE102013004288A1 (de) | 2013-03-13 | 2014-09-18 | Matthias Lietzau | Fahrzeug Verbindungsfolie |
| DE202013002767U1 (de) | 2013-03-22 | 2013-05-28 | Lorenz-Montagesysteme Gmbh | Ausgleichende Seitverbindung von Solarmodulen |
| DE102013005741B3 (de) | 2013-04-05 | 2014-05-22 | IOT - Innovative Oberflächentechnologien GmbH | Vorrichtung zur Inertisierung bei UV-Bestrahlung in offenen Durchlaufanlagen |
| EP2792394B1 (de) | 2013-04-16 | 2016-07-27 | Jörg Beutler | Interaktive Geschwindigkeitssteuerung |
| DE102013104501A1 (de) | 2013-05-02 | 2014-11-06 | B. Braun Avitum Ag | Vorrichtung zur extrakorporalen Blutbehandlung |
| DE102013008359A1 (de) | 2013-05-16 | 2014-11-20 | Sew-Eurodrive Gmbh & Co Kg | Energiespeicher, der aus in Reihe geschalten Energiespeicherzellen aufgebaut ist, und Schaltungsanordnung zur passiven Symmetrierung einer Reihenschaltung von Kondensatoren |
| DE102013008919B4 (de) | 2013-05-24 | 2017-12-07 | Magdeburger Windkraftanlagen GmbH | Rotorsystem für die Energiewandlung von kinetischer Energie in Fluiden und Massenströmen |
| DE202013006258U1 (de) | 2013-07-11 | 2013-10-11 | IMM Ingenieurbüro GmbH | Vorrichtung zum Erzeugen von heizbaren Flächen mit homogener Wärmeverteilung |
| DE102013110693B4 (de) | 2013-09-27 | 2024-04-25 | Heliatek Gmbh | Photoaktives, organisches Material für optoelektronische Bauelemente |
| EP2873807A1 (de) | 2013-11-18 | 2015-05-20 | Siemens Aktiengesellschaft | Abdeckplatte, Laufschaufel, Radscheibe, Bolzen und Gasturbine |
| EP3071392B1 (de) | 2013-11-19 | 2019-09-25 | Fraunhofer Gesellschaft zur Förderung der Angewand | Verfahren zum verbinden von silikongummi mit einem substrat |
| EP2902692B1 (de) | 2013-12-06 | 2017-10-25 | MAGNA STEYR Engineering AG & Co KG | Bauteil eines Tanksystems |
| DE202014100570U1 (de) | 2014-02-10 | 2014-03-10 | Schlaadt Plastics Gmbh | Klappsystem zur Verbindung von Partikelschaumbauteilen mittels eines gegen Verlust gesicherten Steckelements |
| DE102014004280A1 (de) | 2014-03-26 | 2015-10-01 | Florian M. König | Impulssignal-Erzeugungsvorrichtung für Zwecke der autonomen Batterieaufladung oder 120-/230-Volt-Lampenversorgung |
| DE202014003299U1 (de) | 2014-04-14 | 2014-08-25 | Antje Koss | Stollenschuh mit Wechselstollensystem |
| DE202014004532U1 (de) | 2014-05-28 | 2014-08-05 | Hans-Dieter Cornelius | Hygienevorlage |
| DE102015214637A1 (de) | 2014-11-10 | 2016-05-12 | Hermann Roth | Vorrichtung zur Erzeugung eines alkaloidhaltigen Aerosols |
| DE102014017938A1 (de) | 2014-12-05 | 2016-06-09 | Florian M. König | Trichter-turbinenartige Vorrichtung mit elektromagnetischer Rotationssteuerung von Flüssigkeits-Mischvorgängen |
| DE102015000003A1 (de) | 2015-01-02 | 2016-07-07 | Solukon Ingenieure GbR (vertretungsberechtigte Gesellschafter: Andreas Hartmann, 86391 Stadtbergen und Dominik Schmid, 86165 Augsburg) | Baubehälter für Produktionsanlagen zur Herstellung von Bauteilen in Schichtbauverfahren |
| DE102015008129A1 (de) | 2015-01-22 | 2016-07-28 | Liebherr-Hausgeräte Lienz Gmbh | Verfahren zur Bestimmung der Dämmeigenschaft einer Wandung eines wärmeisolierten Behältnisses |
| DE102015000887A1 (de) | 2015-01-23 | 2016-07-28 | Arnulf Deinzer | Zahnreinigungsgerät mit ausfahrbaren Borsten |
| DE102015015877A1 (de) | 2015-12-09 | 2017-06-14 | Bayerisches Zentrum für angewandte Energieforschung, e.V. (ZAE Bayern) | Optisch schaltendes Element |
| DE102016006696A1 (de) | 2016-05-27 | 2017-11-30 | Christoph Jaeger | Flugautosystem |
| DE202016004226U1 (de) | 2016-07-06 | 2016-11-11 | Helmut Senkel | Schienensystem mit verfahrbaren Verbrauchern |
| CN106279585A (zh) * | 2016-08-26 | 2017-01-04 | 宁波圣达精工智能科技有限公司 | 一种阻燃智能密集书架的制备方法 |
| CN108832306B (zh) * | 2018-06-13 | 2023-11-03 | 中国科学院国家天文台 | 一种fast反射面中心孔柔性封堵结构 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EE9800116A (et) * | 1995-10-17 | 1998-10-15 | Astra Pharmaceuticals Limited | Farmatseutiliselt aktiivsed kinasoliini ühendid |
-
1998
- 1998-06-29 SE SE9802333A patent/SE9802333D0/xx unknown
-
1999
- 1999-06-23 WO PCT/SE1999/001144 patent/WO2000000200A1/en not_active Ceased
- 1999-06-23 KR KR1020007014933A patent/KR20010053252A/ko not_active Withdrawn
- 1999-06-23 JP JP2000556785A patent/JP2002519324A/ja active Pending
- 1999-06-23 SK SK1848-2000A patent/SK18482000A3/sk unknown
- 1999-06-23 US US09/380,379 patent/US6248745B1/en not_active Expired - Fee Related
- 1999-06-23 PL PL99345028A patent/PL345028A1/xx not_active Application Discontinuation
- 1999-06-23 ID IDW20002691A patent/ID27394A/id unknown
- 1999-06-23 CN CN99810007A patent/CN1313769A/zh active Pending
- 1999-06-23 BR BR9911666-9A patent/BR9911666A/pt not_active Application Discontinuation
- 1999-06-23 EE EEP200000766A patent/EE200000766A/xx unknown
- 1999-06-23 EP EP99933384A patent/EP1100505A1/en not_active Withdrawn
- 1999-06-23 CA CA002334515A patent/CA2334515A1/en not_active Abandoned
- 1999-06-23 TR TR2000/03808T patent/TR200003808T2/xx unknown
- 1999-06-23 AU AU49447/99A patent/AU4944799A/en not_active Abandoned
- 1999-06-23 CZ CZ20004896A patent/CZ20004896A3/cs unknown
- 1999-06-23 IL IL14002299A patent/IL140022A0/xx unknown
- 1999-06-23 MX MXPA00012162 patent/MXPA00012162A/es unknown
-
2000
- 2000-08-01 IN IN721MU2000 patent/IN2000MU00721A/en unknown
- 2000-11-30 ZA ZA200007076A patent/ZA200007076B/en unknown
- 2000-12-21 NO NO20006559A patent/NO20006559L/no not_active Application Discontinuation
- 2000-12-27 IS IS5794A patent/IS5794A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR9911666A (pt) | 2001-03-20 |
| PL345028A1 (en) | 2001-11-19 |
| EP1100505A1 (en) | 2001-05-23 |
| IN2000MU00721A (enExample) | 2005-03-18 |
| EE200000766A (et) | 2002-06-17 |
| US6248745B1 (en) | 2001-06-19 |
| ID27394A (id) | 2001-04-05 |
| IL140022A0 (en) | 2002-02-10 |
| NO20006559L (no) | 2001-02-28 |
| MXPA00012162A (es) | 2001-05-01 |
| SK18482000A3 (sk) | 2001-07-10 |
| CA2334515A1 (en) | 2000-01-06 |
| ZA200007076B (en) | 2002-02-28 |
| TR200003808T2 (tr) | 2001-06-21 |
| WO2000000200A1 (en) | 2000-01-06 |
| SE9802333D0 (sv) | 1998-06-29 |
| AU4944799A (en) | 2000-01-17 |
| CZ20004896A3 (en) | 2001-06-13 |
| KR20010053252A (ko) | 2001-06-25 |
| IS5794A (is) | 2000-12-27 |
| NO20006559D0 (no) | 2000-12-21 |
| CN1313769A (zh) | 2001-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6248745B1 (en) | Pharmaceutical combination comprising a COX-2 inhibitor and a iNOS inhibitor | |
| JP2001519391A (ja) | 新規な組み合わせ物 | |
| AU715380B2 (en) | Pyrazolopyrimidines for treatment of neuronal and other disorders | |
| JP6532878B2 (ja) | 組合せ医薬 | |
| AU2006212761B2 (en) | Combination therapy | |
| CN105473581A (zh) | 作为溴结构域抑制剂的新取代的双环化合物 | |
| WO2025157289A1 (zh) | 包含prmt5抑制剂和krasg12c抑制剂的药物组合物 | |
| ES2532210T3 (es) | Métodos para el tratamiento concomitante de teofilina y febuxostat | |
| CN103068801A (zh) | 硫代乙酸盐化合物、组合物及其使用方法 | |
| CN108602821A (zh) | 1h-咪唑并[4,5-b]吡啶基和2-氧代-2,3-二氢-1h-咪唑并[4,5-b]吡啶基杂环bet溴结构域抑制剂 | |
| JP2002512957A (ja) | Ｃｃｒ−３受容体アンタゴニスト | |
| TW201912153A (zh) | 用於治療ｂ型肝炎的化合物、醫藥組合物及方法 | |
| TW200927127A (en) | Agent for overcoming resistance to anti-cancer agent | |
| CN101478989A (zh) | 炎性肠病的处置剂 | |
| WO2025157288A1 (zh) | 包含prmt5抑制剂和cdk4/6抑制剂的药物组合物 | |
| JP5129123B2 (ja) | 全身性肥満細胞症の処置のためのピリミジルアミノベンズアミド誘導体の使用 | |
| US20050182125A1 (en) | Pyrrole compounds and uses thereof | |
| ES2203086T3 (es) | Empleo de derivados de tiadiazolo (4,3-a)piridina. | |
| TW202116301A (zh) | 藥物組合及其用途 | |
| WO2021177332A1 (ja) | Ｎｌｒｐ３インフラマソーム阻害剤及び炎症性疾患の予防又は治療のための医薬組成物 | |
| JP2022506289A (ja) | インダゾールキナーゼ阻害剤及びその使用 | |
| KR20080044277A (ko) | 유기 화합물의 조합물 | |
| JP2009500414A (ja) | 有機化合物の組み合わせ | |
| ES3062815T3 (en) | Compositions for treating aging-associated impairments using ccr3-inhibitors | |
| TWI343258B (en) | Combination comprising an active ingredient which decreases the activity of the epidermal growth factor (egf) and an epothilone derivative |